Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of Bucillamine in the treatment of mild-moderate COVID-19 due to the SARS-CoV-2 infection in Canada

Next Previous
X
Search
Trial Profile

A clinical trial of Bucillamine in the treatment of mild-moderate COVID-19 due to the SARS-CoV-2 infection in Canada

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 10 Dec 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bucillamine (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 02 Dec 2020 According to a Revive Therapeutics media release, the company announced the appointment of Dr. Joel Moody as a medical and clinical advisor to the company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (FDA) Phase 3 clinical trial.
    • 09 Jun 2020 According to an Revive Therapeutics media release, the company intends to follow up with the submission of the complete CTA package for Health Canada around the confirmatory Phase 3 study as part of the same multinational clinical strategy.
    • 09 Jun 2020 According to an Revive Therapeutics media release, the Pre-CTA meeting provided an opportunity to discuss Bucillamine's scientific rationale of its potential use in the treatment of COVID-19 infections, Chemistry, Manufacturing and Controls, non-clinical and clinical safety information, and clinical trial design. Health Canada provided valuable guidance on the proposed clinical study design and information required for the submission of a complete CTA package.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top